Company: STAA
Filing Date: 2025-09-24
Form Type: DFAN14A
Source: 0001213900-25-091197
Chunk: 35

Company: STAAR SURGICAL CO
Filing Date: 2025-09-24
Form: DFAN14A
Chunk 35
---
 such as:

| ● | The global myopia epidemic, projected to affect over 5 billion people by 2050 |

| ● | The scarcity value of EVO’s entrenched position |

Seen through this lens, Alcon’s current bid should have been
viewed as a starting point by the STAAR Board, rather than an acceptable endpoint.

A Board focused on maximizing long-term shareholder value might be
expected to use the above arguments to seek improved terms from Alcon—or to invite competing proposals that reflect STAAR’s
strategic scarcity, potential synergies, and credible independent worth.

To settle for less clearly leaves substantial value unavailable to
shareholders and represents a significant gift to Alcon if the deal is approved.

About the Authors

Pascal Aeschlimann

A Singapore based executive who led STAAR Surgical’s business development
efforts in Asia from 2003 to 2010. He later founded SWISSMED, an ophthalmic devices distribution business that became the largest independent
regional player in Southeast Asia, before being acquired by Transmedic in 2022.

As an industry expert, he describes the ICL as the jewel of refractive
surgery. Having gone through a series of acquisition offers for his own business, he understands how unique technologies like the ICL
strengthen the portfolios of strategic acquirers by offering amplified commercial advantages. Pascal.Aeschlimann@gmail.com

David Bailey

A global healthcare and medical device executive with over 40 years
of leadership experience across the U.S., Europe, and Asia. He has held senior roles in ophthalmology, including:

| ● | Launching LASIK in Europe for Chiron Vision |

| ● | Managing Bausch & Lomb’s refractive and surgical business in Europe and Asia |

| ● | Serving as CEO & President of STAAR Surgical, where he led its transformation into a global leader in phakic IOLs over a decade |

As founder of DB Consulting, Mr. Bailey has advised medtech companies
and private equity groups on strategy, M&A, and operational improvement. His track record spans turnarounds, acquisitions, integrations,
and growth strategy—especially in ophthalmology—bringing deep industry knowledge and commercial insight to this evaluation.
Dbailey20102010@hotmail.com.

<div align='center'>3</div>